Showing 1731-1740 of 2054 results for "".
- WaveFront Dynamics Launches WaveDyn Vision Analyzerhttps://modernod.com/news/wavefront-dynamics-launches-wavedyn-vision-analyzer/2481503/WaveFront Dynamics announced the commercial launch of its aberrometry measurement system, the WaveDyn Vision Analyzer. The WaveDyn captures a video of the eye’s optical system over time (rather than just producing a single measurement). The WaveDyn Analyzer’s high resol
- Oertli Launches Updated OS 4 Surgical Platformhttps://modernod.com/news/oertli-launches-os-4-surgical-platform/2481459/Oertli Instrumente announced the release of an updated OS 4 surgical platform for retinal, glaucoma and cataract surgery. Occlusion Mode: Phaco power at the right time The OS 4 offers three phaco modulations as standard. An additional Occlusion Mode
- Post-Hoc Analysis Shows Up to a 59% Reduction in Rate of Vision Loss in Iveric Bio's GA Treatmenthttps://modernod.com/news/iveric-bio-announces-up-to-a-59-reduction-in-rate-of-vision-loss-in-geographic-atrophy-treatment-trials/2481439/Iveric bio announced an exploratory time-to-event analysis from the avacincaptad pegol (ACP) GATHER clinical trial program evaluating reduction in vision loss with ACP 2 mg versus sham treatment. The GATHER1 and GATHER2 clinical trials were designed to evaluate the rate of geographic at
- Glaukos Submits NDA to FDA for iDose TRhttps://modernod.com/news/glaukos-submits-nda-to-fda-for-idose-tr/2481434/Glaukos announced the submission of a new drug application (NDA) to the FDA for iDose TR, a micro-invasive intraocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time.&
- FDA Approves Apellis' Syfovre (Pegcetacoplan), First and Only Treatment for Geographic Atrophyhttps://modernod.com/news/fda-approves-apellis-syfovre-pegcetacoplan-first-and-only-treatment-for-geographic-atrophy/2481421/In a historic approval, for the first time patients with geographic atrophy (GA) will have an FDA-approved treatment option. The FDA on Friday approved Apellis Pharmaceuticals' Syfovre (pegcetacoplan) for the treatment of geographic atrophy (GA) secondary to age-relat
- Clearside Biomedical Announces Leadership Changeshttps://modernod.com/news/clearside-biomedical-announces-leadership-changes/2481386/Clearside Biomedical announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, MD, will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023. In his new advisory capacity, Dr. Ci
- Pixium Vision Announces Publications Demonstrating the Potential of the Next Generation PRIMA Implanthttps://modernod.com/news/pixium-vision-announces-publications-demonstrating-the-potential-of-the-next-generation-prima-implant/2481348/Pixium Vision announced that the second generation of implants for its bionic vision system PRIMA for atrophic age-related macular degeneration (AMD) could restore vision at five times higher resolution than the current PRIMA implants, according to a company news release. Pixi
- Elios Vision Announces Registration of Elios in the United Kingdomhttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-the-united-kingdom/2481318/Elios, a technology used to treat glaucoma at the same time as cataract surgery, is now registered for use in the United Kingdom, according to Elios Vision. The Elios does not require an implant and is designed to provide long-lasting results that may free patients and th
- AAO: Prior Authorization Reform Effort Gets Boost from CMShttps://modernod.com/news/aao-prior-authorization-reform-effort-gets-boost-from-cms/2481310/The Centers for Medicare & Medicaid Services (CMS) released a proposed rule that "closely aligns" with the Improving Seniors’ Timely Access to Care Act (S. 3018/H.R. 3173), a bill the American Academy of Ophthalmology helped craft, according to an AAO news release. If ado
- Elios Vision Announces Registration of Elios in Francehttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-france/2481304/Elios Vision announced that its Elios technology, which is used to treat glaucoma at the same time as cataract surgery, is now registered in France. Elios does not require an implant and is designed to provide long-lasting results that may free patients from drop therapy.